Optimal Therapy Discovered for Vocal Cord Cancer
By MedImaging International staff writers Posted on 09 May 2017 |
The results of a major study comparing radiotherapy treatment options for vocal cord cancer indicate new optimal radiation treatment therapies for the disease.
Current treatment options for Early-Stage Glottic Cancer (ESGC) include both Conventionally-Fractionated Radiotherapy (CFX), and HypoFractionated Radiotherapy (HFX).
The study was published in the April 26, 2017, issue of the Journal of the National Cancer Institute by researchers from the Yale Cancer Center. The researchers used clinical data from a large national database in the US, from the period 2004 to 2013, for the study. The study group consisted of 10,212 patients diagnosed with stage 1 or 2 glottic cancer. Most of the patients, 6,182 (60.5%) in number, were treated with CFX. The rest, 4030 patients (39.5%) were treated with HFX.
The results of the study show that for patients treated with definitive radiotherapy for ESGC cancer, HFX radiotherapy treatment resulted in improved survival compared to CFX radiotherapy treatment. This was especially the case for patients with stage 2 ESGC.
Lead author of the study, Assistant Professor Zain A. Husain, MD, said, “This is an important finding as the optimal fractionation for early stage glottic cancer has long been an area of controversy. These results strongly support hypofractionation as a preferred treatment approach. It is also reassuring to that our results show the utilization of hypofractionation has been increasing considerably.”
Current treatment options for Early-Stage Glottic Cancer (ESGC) include both Conventionally-Fractionated Radiotherapy (CFX), and HypoFractionated Radiotherapy (HFX).
The study was published in the April 26, 2017, issue of the Journal of the National Cancer Institute by researchers from the Yale Cancer Center. The researchers used clinical data from a large national database in the US, from the period 2004 to 2013, for the study. The study group consisted of 10,212 patients diagnosed with stage 1 or 2 glottic cancer. Most of the patients, 6,182 (60.5%) in number, were treated with CFX. The rest, 4030 patients (39.5%) were treated with HFX.
The results of the study show that for patients treated with definitive radiotherapy for ESGC cancer, HFX radiotherapy treatment resulted in improved survival compared to CFX radiotherapy treatment. This was especially the case for patients with stage 2 ESGC.
Lead author of the study, Assistant Professor Zain A. Husain, MD, said, “This is an important finding as the optimal fractionation for early stage glottic cancer has long been an area of controversy. These results strongly support hypofractionation as a preferred treatment approach. It is also reassuring to that our results show the utilization of hypofractionation has been increasing considerably.”
Latest Radiography News
- Novel Breast Imaging System Proves As Effective As Mammography
- AI Assistance Improves Breast-Cancer Screening by Reducing False Positives
- AI Could Boost Clinical Adoption of Chest DDR
- 3D Mammography Almost Halves Breast Cancer Incidence between Two Screening Tests
- AI Model Predicts 5-Year Breast Cancer Risk from Mammograms
- Deep Learning Framework Detects Fractures in X-Ray Images With 99% Accuracy
- Direct AI-Based Medical X-Ray Imaging System a Paradigm-Shift from Conventional DR and CT
- Chest X-Ray AI Solution Automatically Identifies, Categorizes and Highlights Suspicious Areas
- AI Diagnoses Wrist Fractures As Well As Radiologists
- Annual Mammography Beginning At 40 Cuts Breast Cancer Mortality By 42%
- 3D Human GPS Powered By Light Paves Way for Radiation-Free Minimally-Invasive Surgery
- Novel AI Technology to Revolutionize Cancer Detection in Dense Breasts
- AI Solution Provides Radiologists with 'Second Pair' Of Eyes to Detect Breast Cancers
- AI Helps General Radiologists Achieve Specialist-Level Performance in Interpreting Mammograms
- Novel Imaging Technique Could Transform Breast Cancer Detection
- Computer Program Combines AI and Heat-Imaging Technology for Early Breast Cancer Detection